CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

โ† Pharmacyclics, Inc. (PCYC) โ€” catalysts, pipeline & price
Catalyst Dossier ยท compiled by CeliA ๐Ÿงซ

Pharmacyclics, Inc. (PCYC)

Biotechnology ยท market cap โ€”

Research and calibrated estimates, not financial advice โ€” verify before acting.

Next catalyst
2026-12-31 (est.)
Phase 3
Pipeline
20
programs
Upcoming events
3
next 90d+
Dossier
Not yet
generate it
The catalyst path
  • 2026-12-31 (est.)Phase 3 ยท Ibrutinibimp 9/10
  • 2027-03-18 (est.)Phase 3 ยท Ibrutinibimp 9/10
  • 2027-04-15 (est.)Phase 2 ยท Ibrutinibimp 7/10
Pipeline
AssetPhaseIndication
ChlorambucilPhase 3Chronic Lymphocytic Leukemia
Ibrutinib Oral CapsulePhase 3Follicular Lymphoma
PCI-24781Phase 2Lymphoma
MEDI4736Phase 2Diffuse Large B-Cell Lymphoma
Motexafin GadoliniumPhase 3Brain Neoplasms
Motexafin Gadolinium InjectionPhase 2Multiple Myeloma
PCI-27483Phase 2Pancreatic Cancer
MGdPhase 3Metastatic Cancer
PCI-32765Phase 2B-cell Chronic Lymphocytic Leukemia
Next-line ibrutinibPhase 3Chronic Lymphocytic Leukemia
IbrutinibPhase 3Diffuse Large B Cell Lymphoma Relapsed
ofatumumabPhase 3B-cell Chronic Lymphocytic Leukemia
GA101Phase 2Chronic Lymphocytic Leukemia
PCI-32765 (Ibrutinib)Phase 3Lymphoma
BlinatumomabPhase 2Adult B Acute Lymphoblastic Leukemia
Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine AdsorbedPhase 2Chronic Lymphocytic Leukemia
GCSFPhase 2Sarcoma
FludarabinePhase 2Chronic Lymphocytic Leukemia
HD- Methotrexate (MTX)Phase 2Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL)
Cirmtuzumab (2-16 kg/mg) plus IbrutinibPhase 2B-cell Chronic Lymphocytic Leukemia

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks โ€” compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings โ€” EDGAR filings for PCYC (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials โ€” 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data โ€” SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq โ€” prices, statements, key metrics, insider & institutional filings.
  • Regulatory โ€” openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above โ€” verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.

Pharmacyclics, Inc. (PCYC) โ€” Catalyst Dossier | Catalysts, FDA odds, pipeline & financials | CatalystAlert